We have obtained the 37% of CHB patients receiving at least an annual ALT and HBV DNA and 59% percent receiving treatment if eligible from the The Chronic Hepatitis Cohort Study (CHeCS) study by Spradling et al. [16]. This evidence concerns the gene GPT and chronic hepatitis.